FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4376643003> ?p ?o ?g. }

• W4376643003 endingPage "1093" @default.
• W4376643003 startingPage "1091" @default.
• W4376643003 abstract "European Journal of Heart FailureEarly View Invited Editorial Ironing out the wrinkles: unanswered questions in intravenous iron repletion in heart failure Josephine Harrington, Josephine Harrington Duke University Department of Medicine, Division of Cardiology, Durham, NC, USA Duke Clinical Research Institute, Durham, NC, USASearch for more papers by this authorRobert J Mentz, Corresponding Author Robert J Mentz [email protected] Duke University Department of Medicine, Division of Cardiology, Durham, NC, USA Duke Clinical Research Institute, Durham, NC, USA Corresponding author. Duke University School of Medicine, 200 Trent Drive, 4th Floor, Orange Zone, Room 4221, Durham, NC 27710, USA. Email: [email protected]Search for more papers by this author Josephine Harrington, Josephine Harrington Duke University Department of Medicine, Division of Cardiology, Durham, NC, USA Duke Clinical Research Institute, Durham, NC, USASearch for more papers by this authorRobert J Mentz, Corresponding Author Robert J Mentz [email protected] Duke University Department of Medicine, Division of Cardiology, Durham, NC, USA Duke Clinical Research Institute, Durham, NC, USA Corresponding author. Duke University School of Medicine, 200 Trent Drive, 4th Floor, Orange Zone, Room 4221, Durham, NC 27710, USA. Email: [email protected]Search for more papers by this author First published: 16 May 2023 https://doi.org/10.1002/ejhf.2893 The opinions expressed in this article are not necessarily those of the Editors of the European Journal of Heart Failure or of the European Society of Cardiology. doi: 10.1002/ejhf.2860. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL No abstract is available for this article. References 1Jankowska EA, Rozentryt P, Witkowska A, Nowak J, Hartmann O, Ponikowska B, et al. Iron deficiency: An ominous sign in patients with systolic chronic heart failure. Eur Heart J 2010; 31: 1872– 1880. https://doi.org/10.1093/eurheartj/ehq158 2Jankowska EA, Kirwan BA, Kosiborod M, Butler J, Anker SD, McDonagh T, et al. The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: The results of the AFFIRM-AHF study. Eur Heart J 2021; 42: 3011– 3020. https://doi.org/10.1093/eurheartj/ehab234 3Comín-Colet J, Enjuanes C, González G, Torrens A, Cladellas M, Meroño O, et al. Iron deficiency is a key determinant of health-related quality of life in patients with chronic heart failure regardless of anaemia status. Eur J Heart Fail 2013; 15: 1164– 1172. https://doi.org/10.1093/eurjhf/hft083 4Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V, et al.; CONFIRM-HF Investigators. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J 2015; 36: 657– 668. https://doi.org/10.1093/eurheartj/ehu385 5Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, et al.; FAIR-HF Trial Investigators. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009; 361: 2436– 2448. https://doi.org/10.1056/NEJMoa0908355 6Butler J, Khan MS, Friede T, Jankowska EA, Fabien V, Goehring U-M, et al. Health status improvement with ferric carboxymaltose in heart failure with reduced ejection fraction and iron deficiency. Eur J Heart Fail 2022; 24: 821– 832. https://doi.org/10.1002/ejhf.2478 7Anker SD, Ponikowski P, Khan MS, Friede T, Jankowska EA, Fabien V, et al. Responder analysis for improvement in 6-min walk test with ferric carboxymaltose in patients with heart failure with reduced ejection fraction and iron deficiency. Eur J Heart Fail 2022; 24: 833– 842. https://doi.org/10.1002/ejhf.2491 8Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2022; 145: e895– e1032. https://doi.org/10.1161/CIR.0000000000001063 9McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2021; 2022: 4– 131. https://doi.org/10.1093/eurheartj/ehab368 10Ponikowski P, Kirwan BA, Anker SD, McDonagh T, Dorobantu M, Drozdz J, et al.; AFFIRM-AHF Investigators. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: A multicentre, double-blind, randomised, controlled trial. Lancet 2020; 396: 1895– 1904. https://doi.org/10.1016/S0140-6736(20)32339-4 11Anker SD, Kirwan BA, van Veldhuisen DJ, Filippatos G, Comin-Colet J, Ruschitzka F, et al. Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: An individual patient data meta-analysis. Eur J Heart Fail 2018; 20: 125– 133. https://doi.org/10.1002/ejhf.823 12Kalra PR, Cleland JGF, Petrie MC, Thomson EA, Kalra PA, Squire IB, et al.; IRONMAN Study Group. Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): An investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. Lancet 2022; 400: 2199– 2209. https://doi.org/10.1016/S0140-6736(22)02083-9 13Anker SD, Shahzeb Khan M, Butler J, von Haehling S, Jankowska EA, Ponikowski P, et al. Effect of intravenous iron replacement on recurrent heart failure hospitalizations and cardiovascular mortality in patients with heart failure and iron deficiency: A Bayesian meta-analysis. Eur J Heart Fail . https://doi.org/10.1002/ejhf.2860 Published online ahead of print 16/04/23. 14 ClinicalTrials.gov. Intravenous Iron in Patients with Systolic Heart Failure and Iron Deficiency to Improve Morbidity & Mortality (FAIR-HF2). https://clinicaltrials.gov/ct2/show/NCT03036462. Accessed 5 April 2023. 15Mentz RJ, Ambrosy AP, Ezekowitz JA, Lewis GD, Butler J, Wong YW, et al.; HEART-FID Trial Investigators. Randomized placebo-controlled trial of ferric carboxymaltose in heart failure with iron deficiency: Rationale and design. Circ Heart Fail 2021; 14:e008100. https://doi.org/10.1161/CIRCHEARTFAILURE.120.008100 Early ViewOnline Version of Record before inclusion in an issue ReferencesRelatedInformation" @default.
• W4376643003 created "2023-05-17" @default.
• W4376643003 creator A5009193721 @default.
• W4376643003 creator A5084329252 @default.
• W4376643003 date "2023-05-25" @default.
• W4376643003 modified "2023-10-17" @default.
• W4376643003 title "Ironing out the wrinkles: Unanswered questions in intravenous iron repletion in heart failure" @default.
• W4376643003 cites W2002946832 @default.
• W4376643003 cites W2017704094 @default.
• W4376643003 cites W2028265881 @default.
• W4376643003 cites W2148669301 @default.
• W4376643003 cites W2609879055 @default.
• W4376643003 cites W3162717381 @default.
• W4376643003 cites W3164084589 @default.
• W4376643003 cites W4210520398 @default.
• W4376643003 cites W4221034924 @default.
• W4376643003 cites W4221124850 @default.
• W4376643003 cites W4225396975 @default.
• W4376643003 cites W4366083189 @default.
• W4376643003 doi "https://doi.org/10.1002/ejhf.2893" @default.
• W4376643003 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37191130" @default.
• W4376643003 hasPublicationYear "2023" @default.
• W4376643003 type Work @default.
• W4376643003 citedByCount "0" @default.
• W4376643003 crossrefType "journal-article" @default.
• W4376643003 hasAuthorship W4376643003A5009193721 @default.
• W4376643003 hasAuthorship W4376643003A5084329252 @default.
• W4376643003 hasConcept C126322002 @default.
• W4376643003 hasConcept C161191863 @default.
• W4376643003 hasConcept C2778198053 @default.
• W4376643003 hasConcept C2778805511 @default.
• W4376643003 hasConcept C41008148 @default.
• W4376643003 hasConcept C71924100 @default.
• W4376643003 hasConceptScore W4376643003C126322002 @default.
• W4376643003 hasConceptScore W4376643003C161191863 @default.
• W4376643003 hasConceptScore W4376643003C2778198053 @default.
• W4376643003 hasConceptScore W4376643003C2778805511 @default.
• W4376643003 hasConceptScore W4376643003C41008148 @default.
• W4376643003 hasConceptScore W4376643003C71924100 @default.
• W4376643003 hasIssue "7" @default.
• W4376643003 hasLocation W43766430031 @default.
• W4376643003 hasLocation W43766430032 @default.
• W4376643003 hasOpenAccess W4376643003 @default.
• W4376643003 hasPrimaryLocation W43766430031 @default.
• W4376643003 hasRelatedWork W1506200166 @default.
• W4376643003 hasRelatedWork W1995515455 @default.
• W4376643003 hasRelatedWork W2048182022 @default.
• W4376643003 hasRelatedWork W2080531066 @default.
• W4376643003 hasRelatedWork W2604872355 @default.
• W4376643003 hasRelatedWork W2748952813 @default.
• W4376643003 hasRelatedWork W2899084033 @default.
• W4376643003 hasRelatedWork W3031052312 @default.
• W4376643003 hasRelatedWork W3032375762 @default.
• W4376643003 hasRelatedWork W3108674512 @default.
• W4376643003 hasVolume "25" @default.
• W4376643003 isParatext "false" @default.
• W4376643003 isRetracted "false" @default.
• W4376643003 workType "article" @default.